Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis
Aging and disease · 2025
DOI: 10.14336/ad.2024.0440 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Aging and disease, 2025. Verfasst von Jiaqi Xin und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, TDP-43 Proteinopathies, DNA-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) stands as a rare, yet severely debilitating disorder marked by the deterioration of motor neurons (MNs) within the brain and spinal cord, which is accompanied by degenerated corticobulbar/corticospinal tracts and denervation in skeletal muscles. Despite ongoing research efforts, ALS remains incurable, attributed to its intricate pathogenic mechanisms. A notable feature in the pathology of ALS is the prevalence of TAR DNA-binding protein 43 (TDP-43) proteinopathy, detected in approximately 97% of ALS cases, underscoring its significance in the disease's progression. As a result, strategies targeting the aberrant TDP-43 protein have garnered attention as a potential avenue for ALS therapy. This review delves into the existing drug screening systems aimed at TDP-43 proteinopathy and the models employed for drug efficacy validation. It also explores the hurdles encountered in the quest to develop potent medications against TDP-43 proteinopathy, offering insights into the intricacies of drug discovery and development for ALS. Through this comprehensive analysis, the review sheds light on the critical aspects of identifying and advancing therapeutic solutions for ALS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
- Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases; National Key Clinical Department and Key Dis…
- Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong Science Park, Hong Kong, China.
Zitieren
APA
Xin, J., Huang, S., Wen, J., Li, Y., Li, A., Satyanarayanan, S. K., Yao, X., & Su, H. (2025). Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis. Aging and disease. https://doi.org/10.14336/ad.2024.0440
Vancouver
Xin J, Huang S, Wen J, Li Y, Li A, Satyanarayanan SK, et al. Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis. Aging and disease. 2025. doi:10.14336/ad.2024.0440
BibTeX
@article{Xin2025,
author = {Xin, Jiaqi and Huang, Sen and Wen, Jing and Li, Yunhao and Li, Ang and Satyanarayanan, Senthil Kumaran and Yao, Xiaoli and Su, Huanxing},
title = {Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis},
journal = {Aging and disease},
year = {2025},
doi = {10.14336/ad.2024.0440}
}
EUVIMED